Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage

International Journal of Molecular Sciences

Volumn 14, Issue 2, 2013, Pages 3440-3455

  Pastor, Maria Dolores ^a   Nogal, Ana ^a   Molina Pinelo, Sonia ^a   Meléndez, Ricardo ^a   Romero Romero, Beatriz ^b   Mediano, Maria Dolores ^a   López Campos, Jose L ^a,b   García Carbonero, Rocío ^a,b   Sanchez Gastaldo, Amparo ^a,b   Carnero, Amancio ^a,c   Paz Ares, Luis ^a,b  

^a Instituto de Biomedicina de Sevilla   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c Department of Etiology and Biodiversity Conservation   (Spain)

Author keywords

Biomarker; Bronchoalveolar lavage; Inflammation; Lung cancer; Oxidative stress; Proteomics; ROS; Screening

Indexed keywords

BIOLOGICAL MARKER; CATALASE; CATHEPSIN D PREPROTEIN; CYCLOPHILIN A; EZRIN; GLUTATHIONE REDUCTASE; GLUTATHIONE S TRANSFERASE P; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE A2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOCITRATE DEHYDROGENASE 1; LEUKOCYTE ELASTASE INHIBITOR; PEROXIREDOXIN 1; PEROXIREDOXIN 2 ISOFORM A; PEROXIREDOXIN 5; REACTIVE OXYGEN METABOLITE; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 2; THIOREDOXIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; FEMALE; HUMAN; LUNG CANCER; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; UPREGULATION;

EID: 84875088439     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14023440     Document Type: Article

References (57)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Yao, H.; Rahman, I. Current concepts on the role of inflammation in COPD and lung cancer. Curr. Opin. Pharmacol. 2009, 9, 375-383.
3. Pryor, W.A.; Hales, B.J.; Premovic, P.I.; Church, D.F. The radicals in cigarette tar: Their nature and suggested physiological implications. Science 1983, 220, 425-427.
4. Yoshida, T.; Tuder, R.M. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol. Rev. 2007, 87, 1047-1082.
5. Psarras, S.; Caramori, G.; Contoli, M.; Papadopoulos, N.; Papi, A. Oxidants in asthma and in chronic obstructive pulmonary disease (COPD). Curr. Pharm. Des. 2005, 11, 2053-2062.
6. Lee, G.; Walser, T.C.; Dubinett, S.M. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr. Opin. Pulm. Med. 2009, 15, 303-307.
7. Ghezzi, P.; Bonetto, V. Redox proteomics: Identification of oxidatively modified proteins. Proteomics 2003, 3, 1145-1153.
8. Hermans, C.; Dong, P.; Robin, M.; Jadoul, M.; Bernard, A.; Bersten, A.D.; Doyle, I.R. Determinants of serum levels of surfactant proteins A and B and Clara cell protein CC16. Biomarkers 2003, 8, 461-471.
9. Baraibar, M.A.; Hyzewicz, J.; Rogowska-Wrzesinska, A.; Ladouce, R.; Roepstorff, P.; Mouly, V.; Friguet, B. Oxidative stress-induced proteome alterations target different cellular pathways in human myoblasts. Free Radic. Biol. Med. 2011, 51, 1522-1532.
10. Plymoth, A.; Yang, Z.; Lofdahl, C.G.; Ekberg-Jansson, A.; Dahlback, M.; Fehniger, T.E.; Marko-Varga, G.; Hancock, W.S. Rapid proteome analysis of bronchoalveolar lavage samples of lifelong smokers and never-smokers by micro-scale liquid chromatography and mass spectrometry. Clin. Chem. 2006, 52, 671-679.
11. Kelsen, S.G.; Duan, X.; Ji, R.; Perez, O.; Liu, C.; Merali, S. Cigarette smoke induces an unfolded protein response in the human lung: A proteomic approach. Am. J. Respir. Cell Mol. Biol. 2008, 38, 541-550.
12. Pinto-Plata, V.; Toso, J.; Lee, K.; Bilello, J.; Mullerova, H.; De Souza, M.; Vessey, R.; Celli, B. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: Correlation with clinical parameters. Proc. Am. Thorac. Soc. 2006, 3, 465-466.
13. Merkel, D.; Rist, W.; Seither, P.; Weith, A.; Lenter, M.C. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005, 5, 2972-2980.
14. Casado, B.; Iadarola, P.; Pannell, L.K.; Luisetti, M.; Corsico, A.; Ansaldo, E.; Ferrarotti, I.; Boschetto, P.; Baraniuk, J.N. Protein expression in sputum of smokers and chronic obstructive pulmonary disease patients: A pilot study by CapLC-ESI-Q-TOF. J. Proteome Res. 2007, 6, 4615-4623.
15. Hoagland, L.F.M., IV; Campa, M.J.; Gottlin, E.B.; Herndon, J.E., II; Patz, E.F., Jr. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer 2007, 110, 2260-2268.
16. Jessie, K.; Pang, W.W.; Haji, Z.; Rahim, A.; Hashim, O.H. Proteomic analysis of whole human saliva detects enhanced expression of interleukin-1 receptor antagonist, thioredoxin and lipocalin-1 in cigarette smokers compared to non-smokers. Int. J. Mol. Sci. 2010, 11, 4488-4505.
17. Brower, V. Biomarker studies abound for early detection of lung cancer. J. Natl. Cancer Inst. 2009, 101, 11-13.
18. Kang, S.M.; Sung, H.J.; Ahn, J.M.; Park, J.Y.; Lee, S.Y.; Park, C.S.; Cho, J.Y. The Haptoglobin beta chain as a supportive biomarker for human lung cancers. Mol. Biosyst. 2011, 7, 1167-1175.
19. Tian, T.; Hao, J.; Xu, A.; Luo, C.; Liu, C.; Huang, L.; Xiao, X.; He, D. Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci. 2007, 98, 1265-1274.
20. Luo, C.; Urgard, E.; Vooder, T.; Metspalu, A. The role of COX-2 and Nrf2/ARE in anti-inflammation and antioxidative stress: Aging and anti-aging. Med. Hypotheses 2011, 77, 174-178.
21. Kakolyris, S.; Giatromanolaki, A.; Koukourakis, M.; Powis, G.; Souglakos, J.; Sivridis, E.; Georgoulias, V.; Gatter, K.C.; Harris, A.L. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin. Cancer Res. 2001, 7, 3087-3091.
22. Holmgren, A.; Lu, J. Thioredoxin and thioredoxin reductase: Current research with special reference to human disease. Biochem. Biophys. Res. Commun. 2010, 396, 120-124.
23. Malmberg, K.J. Effective immunotherapy against cancer: A question of overcoming immune suppression and immune escape? Cancer Immunol. Immunother. 2004, 53, 879-892.
24. Kim, S.J.; Miyoshi, Y.; Taguchi, T.; Tamaki, Y.; Nakamura, H.; Yodoi, J.; Kato, K.; Noguchi, S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res. 2005, 11, 8425-8430.
25. Lillig, C.H.; Holmgren, A. Thioredoxin and related molecules-From biology to health and disease. Antioxid. Redox. Signal. 2007, 9, 25-47.
26. Jones, D.T.; Pugh, C.W.; Wigfield, S.; Stevens, M.F.; Harris, A.L. Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. Clin. Cancer Res. 2006, 12, 5384-5394.
27. Ceccarelli, J.; Delfino, L.; Zappia, E.; Castellani, P.; Borghi, M.; Ferrini, S.; Tosetti, F.; Rubartelli, A. The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. Int. J. Cancer 2008, 123, 1770-1778.
28. Chaiswing, L.; Bourdeau-Heller, J.M.; Zhong, W.; Oberley, T.D. Characterization of redox state of two human prostate carcinoma cell lines with different degrees of aggressiveness. Free Radic. Biol. Med. 2007, 43, 202-215.
29. Iwasawa, S.; Yamano, Y.; Takiguchi, Y.; Tanzawa, H.; Tatsumi, K.; Uzawa, K. Upregulation of thioredoxin reductase 1 in human oral squamous cell carcinoma. Oncol. Rep. 2011, 25, 637-644.
30. Lincoln, D.T.; Al-Yatama, F.; Mohammed, F.M.; Al-Banaw, A.G.; Al-Bader, M.; Burge, M.; Sinowatz, F.; Singal, P.K. Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. Anticancer Res. 2010, 30, 767-775.
31. Nguyen, P.; Awwad, R.T.; Smart, D.D.; Spitz, D.R.; Gius, D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 2006, 236, 164-174.
32. Welsh, S.J.; Bellamy, W.T.; Briehl, M.M.; Powis, G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002, 62, 5089-5095.
33. Jin, Z.G.; Melaragno, M.G.; Liao, D.F.; Yan, C.; Haendeler, J.; Suh, Y.A.; Lambeth, J.D.; Berk, B.C. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ. Res. 2000, 87, 789-796.
34. Pan, H.; Luo, C.; Li, R.; Qiao, A.; Zhang, L.; Mines, M.; Nyanda, A.M.; Zhang, J.; Fan, G.H. Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration. J. Biol. Chem. 2008, 283, 623-637.
35. Zhu, C.; Wang, X.; Deinum, J.; Huang, Z.; Gao, J.; Modjtahedi, N.; Neagu, M.R.; Nilsson, M.; Eriksson, P.S.; Hagberg, H.; et al. Cyclophilin A participates in the nuclear translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J. Exp. Med. 2007, 204, 1741-1748.
36. Peng, Y.; Li, X.; Wu, M.; Yang, J.; Liu, M.; Zhang, W.; Xiang, B.; Wang, X.; Li, G.; Shen, S. New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer. Mol. Biosyst. 2012, 8, 3077-3088.
37. Strange, R.C.; Spiteri, M.A.; Ramachandran, S.; Fryer, A.A. Glutathione-S-transferase family of enzymes. Mutat. Res. 2001, 482, 21-26.
38. Matsumoto, A.; Okado, A.; Fujii, T.; Fujii, J.; Egashira, M.; Niikawa, N.; Taniguchi, N. Cloning of the peroxiredoxin gene family in rats and characterization of the fourth member. FEBS Lett. 1999, 443, 246-250.
39. Lim, Y.S.; Cha, M.K.; Kim, H.K.; Uhm, T.B.; Park, J.W.; Kim, K.; Kim, I.H. Removals of hydrogen peroxide and hydroxyl radical by thiol-specific antioxidant protein as a possible role in vivo. Biochem. Biophys. Res. Commun. 1 1993, 92, 273-280.
40. Gharib, S.A.; Nguyen, E.; Altemeier, W.A.; Shaffer, S.A.; Doneanu, C.E.; Goodlett, D.R.; Schnapp, L.M. Of mice and men: Comparative proteomics of bronchoalveolar fluid. Eur. Respir. J. 2010, 35, 1388-1395.
41. Garcia, M.; Derocq, D.; Pujol, P.; Rochefort, H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 1990, 5, 1809-1814.
42. Rochefort, H.; Capony, F.; Garcia, M.; Cavailles, V.; Freiss, G.; Chambon, M.; Morisset, M.; Vignon, F. Estrogen-induced lysosomal proteases secreted by breast cancer cells: A role in carcinogenesis? J. Cell Biochem. 1987, 35, 17-29.
43. Berchem, G.; Glondu, M.; Gleizes, M.; Brouillet, J.P.; Vignon, F.; Garcia, M.; Liaudet-Coopman, E. Cathepsin-D affects multiple tumor progression steps in vivo: Proliferation, angiogenesis and apoptosis. Oncogene 2002, 21, 5951-5955.
44. Kim, H.; Kang, H.J.; You, K.T.; Kim, S.H.; Lee, K.Y.; Kim, T.I.; Kim, C.; Song, S.Y.; Kim, H.J.; Lee, C. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 2006, 6, 3466-3476.
45. Zeng, H.; Xu, L.; Xiao, D.; Zhang, H.; Wu, X.; Zheng, R.; Li, Q.; Niu, Y.; Shen, Z.; Li, E. Altered expression of ezrin in esophageal squamous cell carcinoma. J. Histochem. Cytochem. 2006, 54, 889-896.
46. Wang, S.J.; Wu, S.T.; Gokemeijer, J.; Fura, A.; Krishna, M.; Morin, P.; Chen, G.; Price, K.; Wang-Iverson, D.; Olah, T.; et al. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies. Anal. Bioanal. Chem. 2012, 402, 1229-1239.
47. Nicolay, N.; Callaghan, M.A.; Domegan, L.M.; Oza, A.N.; Marsh, B.J.; Flanagan, P.C.; Igoe, D.M.; O'Donnell, J.M.; O'Flanagan, D.M.; O'Hora, A.P. Epidemiology, clinical characteristics and resource implications of pandemic (H1N1) 2009 in intensive care units in Ireland. Crit. Care. Resusc. 2010, 12, 255-261.
48. Wong, K.K.; Jacks, T.; Dranoff, G. NF-kappaB fans the flames of lung carcinogenesis. Cancer Prev. Res. 2010, 3, 403-405.
49. Di Stefano, A.; Caramori, G.; Oates, T.; Capelli, A.; Lusuardi, M.; Gnemmi, I.; Ioli, F.; Chung, K.F.; Donner, C.F.; Barnes, P.J.; et al. Increased expression of nuclear factor-κB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J. 2002, 20, 556-563.
50. Nakanishi, C.; Toi, M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5, 297-309.
51. Denlinger, C.E.; Rundall, B.K.; Jones, D.R. Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: The role of NF-kappaB. Semin. Thorac. Cardiovasc. Surg. 2004, 16, 28-39.
52. Shen, H.M.; Tergaonkar, V. NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009, 14, 348-363.
53. Cheng, Q.; Lee, H.H.; Li, Y.; Parks, T.P.; Cheng, G. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition. Oncogene 2000, 19, 4936-4940.
54. Li, Y.; Ahmed, F.; Ali, S.; Philip, P.A.; Kucuk, O.; Sarkar, F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65, 6934-6942.
55. Osaki, S.; Nakanishi, Y.; Takayama, K.; Pei, X.H.; Ueno, H.; Hara, N. Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell. J. Exp. Clin. Cancer Res. 2003, 22, 69-75.
56. Chen, W.; Wang, X.; Bai, L.; Liang, X.; Zhuang, J.; Lin, Y. Blockage of NF-kappaB by IKKbeta-or RelA-siRNA rather than the NF-κB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells. J. Cell Biochem. 2008, 105, 554-561.
57. Jones, D.R.; Broad, R.M.; Madrid, L.V.; Baldwin, A.S., Jr.; Mayo, M.W. Inhibition of NF-κB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann. Thorac. Surg. 2000, 70, 930-936.